Cardiol Therapeutics (CRDL) EBITDA (2017 - 2026)
Cardiol Therapeutics (CRDL) EBITDA from Jun 30, 2017 to Mar 31, 2026. The TTM Cardiol Therapeutics (CRDL) EBITDA is -$26M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Cardiol Therapeutics (CRDL) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +8.50% |
| 3 Years TTM | +17.08% |
| 5 Years TTM | +9.96% |
| All Time TTM | +37.47% |
Annual EBITDA change of Cardiol Therapeutics (CRDL)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$6.98M | -72.00% |
| 2025 | -$25M | -10.65% |
| 2024 | -$28M | +75.63% |
| 2023 | -$16M | -5.10% |
| 2022 | -$17M | -14.84% |
| 2021 | -$20M | +56.16% |
| 2020 | -$13M | +56.57% |
| 2019 | -$8.04M | +49.75% |
| 2018 | -$5.37M | +350.09% |
| 2017 | -$1.19M | N/A |
Comparison Cardiol Therapeutics (CRDL) five years EBITDA CAGR with competitors
Cardiol Therapeutics (CRDL) five years EBITDA CAGR is 9.96%.